Advertisement
Advertisement
U.S. markets close in 3 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Allakos Inc. (37Z.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
7.18-0.47 (-6.12%)
As of 03:26PM CET. Market open.
Advertisement

Allakos Inc.

975 Island Drive
Suite 201
Redwood City, CA 94065
United States
650 597 5002
https://www.allakos.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees192

Key Executives

NameTitlePayExercisedYear Born
Dr. Robert Alexander Ph.D.CEO & Director1.39M15.59M1970
Dr. Adam L. Tomasi Ph.D.Pres & COO1.06M28.42M1970
Mr. Baird Radford IIIChief Financial Officer484.56kN/AN/A
Dr. Henrik Sandvad RasmussenStrategic AdvisorN/AN/A1959
Dr. Craig Paterson M.D.Chief Medical OfficerN/AN/AN/A
Brad YoungbloodHead of ResearchN/AN/AN/A
Mr. Alan ChangDirector of Medical Affairs & Data AnalyticsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Corporate Governance

Allakos Inc.’s ISS Governance QualityScore as of December 1, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement